TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Being Patient commentary by geriatrician Nathaniel Chin says persistent subjective cognitive decline can warrant a thorough baseline assessment and follow-up, even when cognitive test results are within normal limits. Subjective decline does not establish Alzheimer’s disease, and the supplied report excerpt does not provide evidence that testing or treatment at this stage prevents the disease.
Geriatrician Nathaniel Chin says people who report persistent changes in memory or thinking may merit a fuller assessment and follow-up even when cognitive test scores fall within the normal range. In a Being Patient commentary published October 27, 2026, Chin describes subjective cognitive decline as a possible early window for evaluating risk and potential causes, while stressing that the experience itself does not mean a person has Alzheimer’s disease.
Subjective cognitive decline (SCD) refers to a person’s continuing sense that their cognitive abilities have worsened compared with their earlier level, despite testing that does not show objective impairment. Chin writes that this can include forgetting conversations more often, relying increasingly on notes, or feeling that thinking takes more effort. Those experiences are real to the person, but they do not identify their cause.
Chin cautions that a brief screening test is not the same as a comprehensive cognitive evaluation. Screenings typically take five to 15 minutes and sample a limited set of abilities. A fuller assessment generally takes an hour or longer and can examine memory, language, attention and executive functions such as planning and organizing. In his view, establishing whether SCD is present requires enough testing to check that measurable impairment has not already been overlooked.
Test scores also compare a person with others of a similar age, rather than necessarily comparing them with their own earlier performance. Chin notes that someone whose abilities were once well above average could decline and still score in the average range. Repeated testing against a baseline may help clinicians see whether scores remain stable or change over time, he writes. The commentary presents this as a clinical approach, not as proof that early assessment prevents Alzheimer’s.
Why Normal Scores May Not End Evaluation
The issue matters because a normal result on a single test can be reassuring without fully answering whether a person has experienced a change from their own previous abilities. Chin argues that responding only with “your testing is normal” may miss a chance to document a baseline, review possible contributors and track symptoms over time. This is particularly relevant for people whose concerns persist or are also noticed by someone close to them.
The distinction is also important for avoiding premature conclusions. SCD is a description of perceived change, not a diagnosis of Alzheimer’s, and the commentary lists several other possible influences, including sleep problems, medication effects, depression or anxiety, illness, vascular disease, hearing loss, stress and normal aging. Careful evaluation can help keep both possibilities in view: symptoms should not automatically be dismissed, but they should not be treated as proof of a specific disease either.
Chin frames this period as a potential opportunity to investigate causes and consider appropriate next steps before objective impairment is evident. The source material does not establish that biomarker testing or any intervention in people with SCD prevents Alzheimer’s, nor does it provide study results demonstrating a prevention benefit. Its central point is narrower: persistent concerns can justify assessment and monitoring rather than waiting for test scores to cross an impairment threshold.
Products Worth Considering
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
Hyperice Normatec 3 Leg Compression Boots, Standard Size
As an affiliate, we earn on qualifying purchases.
How Clinicians Distinguish SCD
Chin describes the international Subjective Cognitive Decline Initiative’s concept of “SCD plus”, developed by psychiatrist Frank Jessen and colleagues. The term identifies features that may make subjective decline more concerning as a possible sign of early Alzheimer’s-related change. They include memory-focused complaints, symptoms that began within the past five years, onset at age 60 or older, worry about the change, persistence, seeking medical help and confirmation from someone who knows the person well.
These features do not confirm Alzheimer’s, Chin emphasizes. Their role is to help distinguish patterns that may warrant closer attention from complaints with other possible explanations. The commentary contrasts a person with intermittent word-finding worries over many years, often linked to poor sleep or stress, with someone in their 60s reporting a clearer recent memory change that persists and is also observed by a spouse. Both might score normally; the details and course of their concerns differ.
The supplied excerpt raises the possibility of blood biomarkers, cerebrospinal fluid testing and amyloid PET for selected patients as ways to ask whether Alzheimer’s-related biological changes are present. It ends before describing how those tests should be selected or what results mean. The report therefore supports no specific testing recommendation for every person with SCD.
What SCD Can and Cannot Show
SCD cannot establish Alzheimer’s disease, and the source lists several non-Alzheimer’s explanations for feeling less mentally sharp. Even the SCD-plus features identify a pattern for closer attention; Chin says none proves that Alzheimer’s is present. The commentary excerpt does not quantify how often people with SCD later develop Alzheimer’s or state how accurately the listed features predict that outcome.
The supplied material also stops as it begins discussing biomarkers. It does not explain who should receive blood, spinal-fluid or amyloid PET testing, how clinicians should interpret positive or negative results in a person without measurable impairment, or whether the tests change outcomes at this stage. It provides no trial findings showing that biomarker testing or treatment during SCD prevents dementia. Those questions remain unresolved in the material available here.
Nor does the excerpt set out a standard schedule for repeat cognitive testing or specify which comprehensive assessment is appropriate in each case. Chin’s article offers a physician’s perspective and clinical reasoning; it should not be read as a universal diagnostic protocol or a substitute for an individual medical evaluation.
Evaluation and Follow-Up Questions
Chin’s proposed next steps for persistent SCD include establishing a thorough cognitive baseline, considering other factors that could affect thinking, and, when possible, collecting observations from someone who knows the person well. He also describes repeat testing as useful for assessing whether a person remains stable or shows a consistent change. The article does not prescribe a fixed interval for that follow-up.
For selected patients, clinicians may also consider whether Alzheimer’s-related biomarkers are relevant, but the supplied excerpt does not give criteria for doing so. It remains unclear from this source what further guidance or evidence will address biomarker use and possible prevention or treatment in people with subjective concerns but no objective impairment. For now, the report’s practical message is to take persistent changes seriously without treating them as a diagnosis.
Key Questions
What is subjective cognitive decline?
Subjective cognitive decline means a person feels their memory or thinking has worsened from their earlier level, while cognitive testing does not show objective impairment. It describes an experience, not its cause.
Does subjective cognitive decline mean someone has Alzheimer’s?
No. Chin says SCD is not a diagnosis of Alzheimer’s. Sleep, stress, mood, medications, illness, vascular conditions, hearing loss and aging can also affect how sharp a person feels.
Why might a normal test score not settle the question?
A brief screen samples only some cognitive abilities, and many tests compare a person with others of similar age rather than with their own past performance. Chin says a fuller evaluation and repeated testing may help establish a baseline and track change.
What does “SCD plus” mean?
It describes features that may warrant closer attention, such as persistent, memory-focused concerns that began recently, are worrying to the person, or are also observed by someone close to them. These features do not prove Alzheimer’s, according to Chin.
Can biomarkers detect Alzheimer’s before cognitive impairment?
The commentary excerpt says blood biomarkers, cerebrospinal fluid testing and amyloid PET can be considered as ways to ask whether Alzheimer’s-related biological changes are present in selected patients. It does not specify who should be tested or show that testing or treatment at the SCD stage prevents Alzheimer’s.
Source: beingpatient.com
